Exchange: NASDAQ·Updated 03:59 PM EST
GERN logo

GERN Geron Corp.

$0.9959
$0.0041
(0.41%)
Today
Reported EarningsNov 4
Mkt Cap$644.24M
Vol27.42M

About GERN

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.
41

Bearish Sentiment

How do you feel about GERN?

Garp_
$GERN BioPearl, I have followed you for years on Imetelchat. Just wanted to say MANY THANKS for all your efforts and contributions over those years on the board. Bravo! Also, Godspeed on your health and journey forward!
20
Twillery
$GERN People here and on Yahoo are also ruminating on a share buyback, which I'm almost certain is illegal now because of Geron's contract with Royalty Pharma. There are laws against buybacks while certain loans and contracts exist. When the Royalty contract expires a buyback will become legally possible. And, it's not the time for a buyback anyway.
10
stefano62
$GERN CEO himself Bought 53.5 k shares. Positive sign, even if the Number of stocks acquired Is no so huge https://www.sec.gov/Archives/edgar/data/886744/000180974726000002/xslF345X06/form4-11162026_041101.xml
9
Twillery
$GERN on Imetelchat has a personally sad post concerning his own health, and we must wish him well. Regarding his analysis of Geron's ASH posters, he makes too many unsubstantiated inferences. Perhaps his anticipated fairwell to Imetelchat colored his interpretation of Geron's ASH abstracts and their meaning/significance
11
LianaGray
$GERN A share buyback would be ridiculous right now, and not looked at favorably by the market, though, admittedly, some longtime shareholders with an average of $3 or more might appreciate one; nonetheless, Geron has more important things to do with their money, such as putting it into LR-MDS sales and marketing, educating hematologists, their current pipeline trials, expanded real-world data for label expansion and FDA submission, and more. It would be totally irresponsible for Geron to administer a share buyback now.
11
Twillery
$GERN Geron has pivotal trial results coming soon, but even if the IDMC gives the trial a "continue" instead of a "stop for efficacy," it will be a plus for Geron and its stock. If there's a stop for efficacy, Geron's share price will quintuple, or more, in a day. What's even better is that people suffering from myelofibrosis, specifically intermediate-2 (INT-2) or high-risk (HR) myelofibrosis, may have found a cure, or as close to a cure as possible.
11
BubblesMcGee123
$GERN I really do wonder what will happen to Geron's IMproveMF trial if its Phase 1b results are good. Geron wants to direct its cash to building its LR-MDS franchise, which makes sense, so providing positive 1b results, I hope Geron's CEO finds a Big Pharma to fund IMproveMF.
10
Kaladude
$GERN Zacks just changed it rating to a 2 buy was 4 sell a month ago before the phase 3 neg news then a 3 hold for the past couple of years have been early to know …
10
ptcamd1
$GERN interesting that there were not more questions today. I think everyone knows the answer. Undervalued and oversold. Recommendations forthcoming
10
Kazarius
$GERN if mid to high end of the $220-$240 range is $235M, then Q4 would be $65.6M. That’s a considerable jump. If it’s sustainable we may hit the analysts’ base case of $340M next year. Hope they cover more details on their UK/EU plans on this call.
10
BubblesMcGee123
$GERN After reading more since October 28th, I now think Geron still has choices, and a buyout under $5 per share would seem hasty: ”Analysts at GlobalData, parent company of Clinical Trials Arena, currently forecast a blockbuster future for Rytelo, with expectations the drug will pull in sales of $1.2BN in 2032." Plenty of biotech with one indication are sold at higher prices.
10
BubblesMcGee123
$GERN Are you being serious? Have you ever known any with cancer, let alone terminal cancer? Every moment becomes a moment that the critically ill want to endow with meaning, with joy. They seek to reconcile with family and friends, play with grandchildren, grasp onto memories, endow everyday activities with significance.
10
vonryan
$GERN Its madness that GERN have been slam so hard. A freaky company with a cancer drug in play and its earnings coming soon. The last earnings report the stock rose 20%. Very frustrating but i just brought more on the far dip. best to all.
10
Gernbcrx
$GERN I think everyone is missing a very important point with the FDA discussion and timeline. GERN is trtingnto reach consensus with BOTH the FDA and EMA. Gerring boths blessing on the change, whatever that may be, requires EMA to be onboars to and they never move fast
10
LianaGray
$GERN I didn't know the following until this week, but it was eye-opening: I had thought that any offers to buy Geron, or any company, had to be divulged to shareholders because a prospective buyout would be material information, and if not right away, divulged eventually. I just learned that Geron can be the recipient of buyout offers that never have to be dilvuged, that not all material info must be announced. I don't understand the intricate rules, but that's the bottom line.
9
Kazarius
$GERN $GERN November corporate presentation is up with a refreshed look and several positive updates vs. October: 1. Patent protection: New slides highlight U.S. protection through 2039 and EU protection through 2038. 2. Earlier-line adoption: 1st/2nd-line patient starts increased to 36% from 34%. 3. Operating expenses: 2026 guidance lowered by $10M to $220–230M. 4. Prescribing accounts: Increased to ~1,700 from ~1,575. Encouraging signs of continued commercial progress and improved financial discipline.
9
TraderAP
$GERN The comments around business development worry me. The vast majority of acquisitions fail to drive any shareholder value. I would much rather see the company use some of their cash position to buy back shares, and reduce the very considerable float we have.
9
BEATWALLSTREET
$GERN I’ve been watching this for about 3 months now. I was so close to pulling the trigger yesterday, but I waited until today. Boom! 80K shares at $0.90. Buyout target: $3–$5. Mark it!
9
Roaring_Capybara
$GERN I'm not greedy, I'll settle for a few % green every day this week. Then, just one 150% day next week.
9
Rdww2011
$GERN Goldman telling their clients about their new price targets today before releasing to public next week?? my guess, $2.50 …
8

Advertisement|Remove ads.